Balto Pharmaceuticals, Inc.
Balto Pharmaceuticals is a biotech company dedicated to improving patient outcomes by developing first-in-class small molecule inhibitors of protein-protein interactions for the safe and effective treatment of cancer.
Industries
manufacturing
medical
pharmaceutical
Nr. of Employees
small (1-50)
Balto Pharmaceuticals, Inc.
Products
PP2D Platform
A proprietary platform for discovering small molecule inhibitors and degraders targeting protein-protein interactions in cancer and other diseases.
Small Molecule PPI Inhibitors
First-in-class small molecules developed to inhibit and degrade critical cancer drivers, functioning as monovalent targeted protein degraders.
PP2D Platform
A proprietary platform for discovering small molecule inhibitors and degraders targeting protein-protein interactions in cancer and other diseases.
Small Molecule PPI Inhibitors
First-in-class small molecules developed to inhibit and degrade critical cancer drivers, functioning as monovalent targeted protein degraders.
Expertise Areas
- Protein–protein interaction (PPI) inhibitor discovery
- Oncology drug discovery
- Platform-driven target discovery
- Preclinical development
Key Technologies
- Small-molecule drug discovery
- Platform-based screening for challenging targets
- Target validation assays
- Lead optimization workflows